The Role of Adjuvant Radiation Therapy for Locoregionally Advanced Papillary Thyrorid Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Nam Kwon | - |
dc.contributor.author | Kim, Chul Yong | - |
dc.contributor.author | Baek, Seung-Kuk | - |
dc.contributor.author | Jung, Kwang-Yoon | - |
dc.date.accessioned | 2021-09-04T04:59:12Z | - |
dc.date.available | 2021-09-04T04:59:12Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/90136 | - |
dc.description.abstract | Objectives: To investigate the role of adjuvant radiation therapy in locoregional control in patients with locoregionally advanced papillary thyroid carcinoma (pT4 or pN1b) based on a comparison of a group that received radiation therapy and a group that did not receive radiation therapy. Methods: A retrospective analysis was performed on 165 patients with locoregionally advanced papillary thyroid carcinoma who underwent treatment between 2002 and 2011. Of these, 32 patients received adjuvant radiation therapy, and 133 patients did not receive radiation therapy. Results: The median follow-up period was 7.2 years (range, 3.4-13.6) for the overall study population. The 10-year locoregional recurrence-free survival rates for patients in the radiation therapy and no radiation therapy groups were 83.9 and 60.8%, respectively (p = 0.037). The overall survival rate and distant recurrence-free survival rate were not different between the two groups (p = 0.076 and p = 0.813, respectively). Multivariate analysis showed that adjuvant radiation therapy was an independent prognostic factor for locoregional recurrence-free survival (p = 0.040). Conclusions: Adjuvant radiation therapy for patients with either pT4 or pN1b disease improved locoregional recurrence-free survival and might be of benefit for patients with these high-risk features by reducing the need for additional salvage treatment after locoregional recurrence. (C) 2016 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | EXTERNAL-BEAM RADIOTHERAPY | - |
dc.subject | LYMPH-NODE INVOLVEMENT | - |
dc.subject | CANCER | - |
dc.subject | IMPACT | - |
dc.subject | SURVIVAL | - |
dc.title | The Role of Adjuvant Radiation Therapy for Locoregionally Advanced Papillary Thyrorid Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Nam Kwon | - |
dc.contributor.affiliatedAuthor | Kim, Chul Yong | - |
dc.contributor.affiliatedAuthor | Baek, Seung-Kuk | - |
dc.contributor.affiliatedAuthor | Jung, Kwang-Yoon | - |
dc.identifier.doi | 10.1159/000444393 | - |
dc.identifier.scopusid | 2-s2.0-84961218405 | - |
dc.identifier.wosid | 000374511300005 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, v.90, no.4, pp.209 - 214 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.citation.title | ONCOLOGY | - |
dc.citation.volume | 90 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 209 | - |
dc.citation.endPage | 214 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | EXTERNAL-BEAM RADIOTHERAPY | - |
dc.subject.keywordPlus | LYMPH-NODE INVOLVEMENT | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Papillary thyroid carcinoma | - |
dc.subject.keywordAuthor | Radiation therapy | - |
dc.subject.keywordAuthor | Locoregional control | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.